
		At p. 16, replace line 14 with the following:	
91	(g)	gly-gly-gly-gly-gly-gly (SEQ ID NO: 12);	
		At p. 16, replace line 16 with the following:	
B5_	(i)	gly-gly-pro-gly-gly (SEQ ID NO: 13);.	
		At p. 16, replace lines 18 and 19 with the following:	
BG	(k)	ser-gly-gly-gly-gly-gly-gly-gly (SEQ ID NO: 14);.	
. 1.		At p. 16, replace lines 20 and 21 with the following:	
B7_	(1)	gly-gly-ser-gly-ser-gly-ala-gly-ser-gly-ser-gly-ser-gly-ser-gly-gly (SEQ ID NO: 15);.	
	•		
	<u>In the</u>	claims:	
		Please cancel Claims 2, 17-20 and 22 without prejudice as being drawn to a non-elected	
	invent		
		Please cancel Claims 1, 3-16 and 21 without prejudice.	
	٠٠ .		
		Please add the following claims:	
		23. A method of preventing or treating loss of bone mass resulting from lytic bone disease in a	
		nal comprising administering a therapeutically effective amount of an OPG polypeptide and a therapeutically	
	effecti	ive amount of a cancer therapy agent.	
,		24. A method for preventing abnormal bone formation associated with cancer in a mammal	
\mathcal{A}	•	ising administering a therapeutically effective amount of an OPG polypeptide and a therapeutically effective	
\mathcal{L}°	amou	nt of a cancer therapy agent.	
/ ¹		4	
		25. The method of Claims 23 or 24 wherein the OPG polypeptide comprises an amino acid	
	seque	ence as shown in Figure 2 (SEQ ID NO: 2) or a truncated polypeptide thereof.	
		26. The method of Claims 23 or 24 wherein the OPG polypeptide comprises an amino acid	
	seque	ence from residues 22 to 401 inclusive as shown in Figure 2 (SEQ ID NO: 2) or a truncated polypeptide thereof.	

PATENT APPLICATION



cancer, prostate cancer, thyroid cancer, cancer of the kidney, lung cancer, esophogeal cancer, rectal cancer,

and lymphoma.

bladder cancer, cervical cancer, ovarian cancer, liver cancer, cancer of the gastrointestinal tract, multiple myeloma,

PATENT APPLICATION

38. The method of Claims 23 or 24 wherein the cancer therapy agent is chemotherapy.

39. The method of Claim 38 wherein phemotherapy comprises anthracyclines, taxol, tamoxifene,

doxorubicin, and 5-fluorouracil.

" bodiler

40. The method of Claims 23, 24 or 30 wherein the therapeutically effective amount of an OPG

polypeptide or an OPG fusion polypeptide is from about 0 1 mg/kg to about 10 mg/kg.